Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations ...

Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM – Research Report) and Amgen (AMGN – Research ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a ...

The Dow Jones Industrial Average is declining Wednesday morning with shares of Amgen and Merck seeing the biggest losses for the price-weighted average.

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $330 from $328 and keeps an Equal Weight rating on the ...